Rakuten Investment Management Inc. Increases Stock Position in Johnson & Johnson $JNJ

Key Points

• Rakuten Investment Management increased its Johnson & Johnson position by 10.1% in the second quarter, adding 36,182 shares to reach 393,806 shares valued at approximately $101.8 million. Institutional investors collectively own 69.55% of J&J stock.
• Johnson & Johnson reported quarterly EPS of $2.90 and revenue of $25.31 billion, exceeding analyst expectations, while revenue rose 6.6% year over year. The company maintained fiscal 2026 EPS guidance of $11.60–$11.75.
• The company declared a quarterly dividend of $1.34 per share, equivalent to an annualized $5.36 and a 1.9% yield. Analysts hold a “Moderate Buy” consensus rating with an average price target of $272.83.

Rakuten Investment Management Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 393,806 shares of the company's stock after purchasing an additional 36,182 shares during the quarter. Johnson & Johnson comprises 0.3% of Rakuten Investment Management Inc.'s investment portfolio, making the stock its 20th largest holding. Rakuten Investment Management Inc.'s holdings in Johnson & Johnson were worth $101,803,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of JNJ. Elefante Mark B lifted its position in Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after acquiring an additional 2,563 shares during the period. World Investment Advisors increased its holdings in shares of Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company's stock valued at $33,390,000 after purchasing an additional 26,450 shares during the period. Signal Advisors Wealth LLC increased its holdings in shares of Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock valued at $3,697,000 after purchasing an additional 6,539 shares during the period. Gradient Investments LLC raised its stake in shares of Johnson & Johnson by 9.9% during the second quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after purchasing an additional 13,737 shares during the last quarter. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Johnson & Johnson during the first quarter worth $30,017,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $275.12 on Tuesday. Johnson & Johnson has a one year low of $173.33 and a one year high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The business has a fifty day moving average of $262.32 and a two-hundred day moving average of $245.30. The company has a market cap of $663.01 billion, a P/E ratio of 31.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Bank of America boosted their price objective on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a research note on Friday, July 10th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research note on Thursday, July 16th. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, UBS Group started coverage on shares of Johnson & Johnson in a research report on Wednesday, September 2nd. They issued a "buy" rating and a $320.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $272.83.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 97,569 shares of company stock valued at $25,476,044 in the last 90 days. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.